Serum neutralisation of the SARS-CoV-2 omicron sublineage BA.2
Lancet Microbe
.
2022 Jun;3(6):e404.
doi: 10.1016/S2666-5247(22)00060-X.
Epub 2022 Mar 28.
Authors
Lin-Lei Chen
1
2
,
Allen Wing-Ho Chu
1
2
,
Ricky Rui-Qi Zhang
3
,
Ivan Fan-Ngai Hung
3
,
Kelvin Kai-Wang To
1
2
4
5
6
Affiliations
1
State Key Laboratory for Emerging Infectious Diseases, The University of Hong Kong, Hong Kong Special Administrative Region, China.
2
School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China.
3
Department of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China.
4
Department of Microbiology, Queen Mary Hospital, Hong Kong Special Administrative Region, China.
5
Department of Clinical Microbiology and Infection Control, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China.
6
Centre for Virology, Vaccinology and Therapeutics, Hong Kong Science and Technology Park, Hong Kong Special Administrative Region, China.
PMID:
35373159
PMCID:
PMC8959473
DOI:
10.1016/S2666-5247(22)00060-X
No abstract available
Publication types
Research Support, Non-U.S. Gov't
Letter
MeSH terms
COVID-19*
Humans
SARS-CoV-2*
Spike Glycoprotein, Coronavirus
Substances
Spike Glycoprotein, Coronavirus
spike protein, SARS-CoV-2